Meto's Take: What This Means for Women Seeking Answers Women consistently arrive at Meto carrying a constellation of symptoms persistent fatigue, weight shifts despite careful eating, irregular cycles, disrupted sleep, low libido after being told their labs are "normal." The emerging peptide science is confirming what many of these women have already sensed: their endocrine and metabolic systems are under strain that standard screening does not capture
Data expressed as (mean SD, n = 6)
Approval (2017) Once-Weekly Semaglutide in Adults With Overweight or Obesity (March 2021) Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation (June 25, 2021) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (November 11, 2023) Ozempic Side Effects Two-Year Effects Of Semaglutide In Adults With Overweight Or Obesity: The STEP 5 Trial (October 10, 2022) The Pathophysiology Of Chronic Constipation (October 2011) Dietary Guidelines for Americans, 2020-2025
At the receptor level, cagrilintide is a non-selective agonist of the calcitonin receptor (CTR) and amylin receptors (AMYRs)
They arent replacements for traditional therapies, but precision tools that can enhance them
